{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:50:07Z","timestamp":1769194207100,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10067-020-05171-8","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T06:03:32Z","timestamp":1590473012000},"page":"3643-3652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece"],"prefix":"10.1007","volume":"39","author":[{"given":"Prodromos","family":"Sidiropoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Athanassiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Koutsianas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Petrikkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evripidis","family":"Kaltsonoudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"10055","key":"5171_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"5171_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2474-11-98","volume":"11","author":"I Anagnostopoulos","year":"2010","unstructured":"Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, Barouta G, Sakkas LI (2010) The prevalence of rheumatic diseases in Central Greece: a population survey. BMC Musculoskelet Disord 11:98. https:\/\/doi.org\/10.1186\/1471-2474-11-98","journal-title":"BMC Musculoskelet Disord"},{"issue":"12","key":"5171_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/rheumatology\/kel140","volume":"45","author":"A Andrianakos","year":"2006","unstructured":"Andrianakos A, Trontzas P, Christoyannis F, Kaskani E, Nikolia Z, Tavaniotou E, Georgountzos A, Krachtis P (2006) Prevalence and management of rheumatoid arthritis in the general population of Greece--the ESORDIG study. Rheumatology (Oxford) 45(12):1549\u20131554. https:\/\/doi.org\/10.1093\/rheumatology\/kel140","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5171_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O\u2019Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"5171_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5171_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","volume":"54","author":"J Bluett","year":"2015","unstructured":"Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Cordingley L, Barton A (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate cohort. Rheumatology (Oxford) 54(3):494\u2013499. https:\/\/doi.org\/10.1093\/rheumatology\/keu358","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5171_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/rheumatology\/kep354","volume":"49","author":"S Scarpato","year":"2010","unstructured":"Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, Bazzichi L, Minisola G, Matucci CM (2010) Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 49(2):289\u2013294. https:\/\/doi.org\/10.1093\/rheumatology\/kep354","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5171_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x","journal-title":"Value Health"},{"key":"5171_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/PPA.S128665","volume":"11","author":"A Svedbom","year":"2017","unstructured":"Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A (2017) Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Prefer Adherence 11:719\u2013729. https:\/\/doi.org\/10.2147\/PPA.S128665","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"5171_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D\u2019Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47(1):108\u2013114. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.008","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5171_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semarthrit.2017.03.010","volume":"47","author":"GS Calip","year":"2017","unstructured":"Calip GS, Adimadhyam S, Xing S, Rincon JC, Lee WJ, Anguiano RH (2017) Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum 47(2):157\u2013164. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.010","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"5171_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 55(3):523\u2013534. https:\/\/doi.org\/10.1093\/rheumatology\/kev374","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"5171_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P (2014) Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic registry of biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43(4):447\u2013457. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.07.011","journal-title":"Semin Arthritis Rheum"},{"key":"5171_CR14","doi-asserted-by":"publisher","unstructured":"Bolge SC, Goren A, Tandon N (2015) Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence 9121\u20139131. https:\/\/doi.org\/10.2147\/PPA.S70834","DOI":"10.2147\/PPA.S70834"},{"issue":"Suppl 1","key":"5171_CR15","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/ddr.21192","volume":"75","author":"M Biggioggero","year":"2014","unstructured":"Biggioggero M, Favalli EG (2014) Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 75(Suppl 1):S38\u2013S41. https:\/\/doi.org\/10.1002\/ddr.21192","journal-title":"Drug Dev Res"},{"issue":"4","key":"5171_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/rheumatology\/keh554","volume":"44","author":"T Kennedy","year":"2005","unstructured":"Kennedy T, McCabe C, Struthers G, Sinclair H, Chakravaty K, Bax D, Shipley M, Abernethy R, Palferman T, Hull R (2005) BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology (Oxford) 44(4):553\u2013556. https:\/\/doi.org\/10.1093\/rheumatology\/keh554","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5171_CR17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5171_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMct055183","volume":"355","author":"DL Scott","year":"2006","unstructured":"Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355(7):704\u2013712. https:\/\/doi.org\/10.1056\/NEJMct055183","journal-title":"N Engl J Med"},{"issue":"2","key":"5171_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2012.11.007","volume":"16","author":"F Augustovski","year":"2013","unstructured":"Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, Lencina V, Scolnik M, Waimann C, Navarta D, Citera G, Soriano ER (2013) Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health 16(2):385\u2013393. https:\/\/doi.org\/10.1016\/j.jval.2012.11.007","journal-title":"Value Health"},{"issue":"2","key":"5171_CR20","first-page":"84","volume":"9","author":"AM Louder","year":"2016","unstructured":"Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, Pasquale MK (2016) Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 9(2):84\u201393","journal-title":"Am Health Drug Benefits"},{"key":"5171_CR21","doi-asserted-by":"publisher","unstructured":"Bolge SC, Goren A, Brown D, Ginsberg S, Allen I (2016) Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. Patient Prefer Adherence 101079\u2013101090. https:\/\/doi.org\/10.2147\/PPA.S107790","DOI":"10.2147\/PPA.S107790"},{"issue":"4","key":"5171_CR22","first-page":"579","volume":"35","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D (2017) Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 35(4):579\u2013585","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5171_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44\u201348. https:\/\/doi.org\/10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"5171_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"120","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 120:20. https:\/\/doi.org\/10.1186\/1477-7525-1-20","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"5171_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM van Gestel","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van\u2019t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34\u201340. https:\/\/doi.org\/10.1002\/art.1780390105","journal-title":"Arthritis Rheum"},{"key":"5171_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"212","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 212:12. https:\/\/doi.org\/10.1186\/1477-7525-2-12","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"5171_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/rheumatology\/keh412","volume":"44","author":"M Ahlmen","year":"2005","unstructured":"Ahlmen M, Nordenskiold U, Archenholtz B, Thyberg I, Ronnqvist R, Linden L, Andersson AK, Mannerkorpi K (2005) Rheumatology outcomes: the patient\u2019s perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology (Oxford) 44(1):105\u2013110. https:\/\/doi.org\/10.1093\/rheumatology\/keh412","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5171_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rheumatology\/keh412","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA (2008) Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6(1):1\u201314. https:\/\/doi.org\/10.1093\/rheumatology\/keh412","journal-title":"Musculoskeletal Care"},{"issue":"Suppl 2","key":"5171_CR29","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1186\/ar996","volume":"6","author":"S Schwartzman","year":"2004","unstructured":"Schwartzman S, Morgan GJ Jr (2004) Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 6(Suppl 2):S19\u2013S23. https:\/\/doi.org\/10.1186\/ar996","journal-title":"Arthritis Res Ther"},{"key":"5171_CR30","doi-asserted-by":"publisher","unstructured":"Huynh TK, Ostergaard A, Egsmose C, Madsen OR (2014) Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 893\u2013899. https:\/\/doi.org\/10.2147\/PPA.S55156","DOI":"10.2147\/PPA.S55156"},{"issue":"12","key":"5171_CR31","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/rheumatology\/kel369","volume":"45","author":"EL Williams","year":"2006","unstructured":"Williams EL, Edwards CJ (2006) Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford) 45(12):1575\u20131576. https:\/\/doi.org\/10.1093\/rheumatology\/kel369","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"5171_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dalen","year":"2016","unstructured":"Dalen J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S (2016) Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int 36(7):987\u2013995. https:\/\/doi.org\/10.1007\/s00296-016-3423-5","journal-title":"Rheumatol Int"},{"issue":"5","key":"5171_CR33","first-page":"791","volume":"30","author":"CM Barbosa","year":"2012","unstructured":"Barbosa CM, Terreri MT, Rosario PO, de Moraes-Pinto MI, Silva CA, Hilario MO (2012) Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol 30(5):791\u2013798","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5171_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.31138\/mjr.29.1.27","volume":"29","author":"K Thomas","year":"2018","unstructured":"Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, Katsimbri P, Boumpas DT, Tsatsani P, Gazi S, Fragkiadaki K, Tektonidou M, Sfikakis PP, Pantazi L, Boki KA, Grika EP, Vlachoyiannopoulos PG, Karagianni K, Sakkas LI, Dimitroulas T, Garyfallos A, Kassimos D, Evangelatos G, Iliopoulos A, Areti M, Georganas K, Melissaropoulos K, Georgiou P, Vounotrypidis P, Ntelis K, Mavragani C, Kitas GD, Vassilopoulos D (2018) Multicenter cross-sectional study of patients with rheumatoid arthritis in Greece: results from a cohort of 2.491 patients. Mediterr J Rheumatol 29(1):27\u201337. https:\/\/doi.org\/10.31138\/mjr.29.1.27","journal-title":"Mediterr J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05171-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:50:20Z","timestamp":1621986620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05171-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5171"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05171-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"16 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Evangelia Petrikou was employed by Merck Sharp & Dohme (MSD) Greece. All other authors declare no competing interests.Ethical approval was provided by the local institutional boards of participating centres, and informed consent was provided by all patients before their inclusion in the study and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}